Because of a unique pharmacodynamic profile, amisulpride seems appropriate for treatment of elderly patients with schizophrenia. In a large-scale naturalistic therapeutic drug monitoring study, daily amisulpride dose, trough and dose-corrected amisulpride plasma levels, co-medication, clinical effectiveness (CGI) and side effects (UKU) were compared between age groups in 395 patients with schizophrenia or schizoaffective disorder (46% women; mean age 39.1 ± 14.2 years, range 18–83 years) under amisulpride therapy. Mean amisulpride doses (574 ± 269 mg/day), plasma levels (304 ± 274 ng/mL), dose-corrected amisulpride plasma levels (C/D ratios, 0.52 ± 0.41 ng/mL:mg), clinical response (at least moderate improvement, 71.6%), and side effects (any side effect, 32.2%; extrapyramidal symptoms, 14.9%) were comparable between age groups (P > 0.25). At higher age, significantly more benzodiazepines (P = 0.04), non-benzodiazepine hypnotics (P = 0.004) and non-psychotropic medications (P < 0.0001) were prescribed. The naturalistic study showed higher C/D ratios in women (P = 0.019) and a slight increase of C/D ratios with age (P = 0.026), but no substantial age-dependent effects on amisulpride doses or plasma levels. In patients above 60 years, clinical response was associated with lower amisulpride plasma levels (P = 0.016) at comparable doses. Neither the age-dependent decrease of amisulpride clearance nor the significantly higher prevalence of co-morbidity and co-medication seem to be the reasons for definite clinical concerns against amisulpride treatment of elderly if contraindications are seriously taken.
Adler G (2001) Paranoide Störungen im höheren Lebensalter.Stuttgart: Schattauer.
2.
Alexopoulos GS Streim J Carpenter D Docherty JP . ; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients (2004) Using antipsychotic agents in older patients.J Clin Psychiatry65(Suppl. 2): 5–99.
3.
Bergemann N Kopitz J Kress KR Frick A (2004) Plasma amisulpride levels in schizophrenia or schizoaffective disorder.Eur Neuropsychopharmacol14: 245–250.
4.
Bergemann N Kress KR Frick A Kopitz J (2005) Amisulpride has no effect on plasma clozapine concentrations.J Clin Psychopharmacol25: 494–497.
5.
Bonati M Clavenna A (2005) The epidemiology of psychotropic drug use in children and adolescents.Int Rev Psychiatry17: 181–188.
6.
Caccia S (2000) Biotransformation of post-clozapine antipsychotics: pharmacological implications.Clin Pharmacokinet38: 393–414.
7.
Caccia S (2002) New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.Curr Opin Investig Drugs3: 1073–1080.
8.
Canal M Legangneux E van Lier JJ van Vliet AA Coulouvrat C (2003) Lack of effect of amisulpride on the pharmacokinetics and safety of lithium.Int J Neuropsychopharmacol6: 103–109.
9.
Chan YC Pariser SF Neufeld G (1999) Atypical antipsychotics in older adults.Pharmacotherapy19: 811–822.
10.
Craig D Passmore AP Fullerton KJ Beringer TR Gilmore DH Crawford VL (2003) Factors influencing prescription of CNS medications in different elderly populations.Pharmacoepidemiol Drug Saf12: 383–387.
11.
Davis JM Chen N Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics.Arch Gen Psychiatry60: 553–564.
12.
El-Ela AA Härtter S Schmitt U Hiemke C Spahn-Langguth H Langguth P (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds–implications for pharmacokinetics of selected substrates.J Pharm Pharmacol56: 967–975.
13.
FDA (2005) New warning on antipsychotic drugs used to treat older people.FDA Consum Mag39: 2–3.
14.
Forsell Y Henderson AS (1998) Epidemiology of paranoid symptoms in an elderly population.Br J Psychiatry172: 429–432.
15.
Fulton MM Allen ER (2005) Polypharmacy in the elderly: a literature review.J Am Acad Nurse Pract17: 123–132.
16.
Gill SS Rochon PA Herrmann N Lee PE Sykora K Gunraj N (2005) Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.BMJ330: 445–450.
17.
D Guy , (ed) (1976) ECDEU Assessment Manual for Psychopharmacology, revised. NIMH, Rockville: DHEU Publication.
18.
Häfner H Löffler W Riecher-Rössler A Häfner-Ranabauer W (2001) Schizophrenia and delusions in middle aged and elderly patients. Epidemiology and etiological hypothesis.Nervenarzt72: 347–357.
19.
Hamon-Vilcot B Chaufour S Deschamps C Canal M Zieleniuk I Ahtoy P (1998) Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers.Eur J Clin Pharmacol54: 405–409.
20.
Hiemke C Dragicevic A Gründer G Härtter S Sachse J Vernaleken I Müller MJ (2004) Therapeutic monitoring of new antipsychotic drugs.Ther Drug Monit26: 156–160.
21.
Jeste DV Dolder CR Nayak GV Salzman C (2005) Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.Harv Rev Psychiatry13: 340–351.
22.
Kampmann J Siersbaek-Nielsen K Kristensen M Hansen JM (1974) Rapid evaluation of creatinine clearance.Acta Med Scand196: 517–520.
23.
Lader MH (1999) Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?Eur Neuropsychopharmacol9(Suppl. 6): S399–S405.
24.
Lake JT Rahman AH Grossberg GT (1997) Diagnosis and treatment of psychotic symptoms in elderly patients.Drugs Aging11: 170–177.
25.
Legangneux E McEwen J Wesnes KA Bergougnan L Miget N Canal M (2000) The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers.J Psychopharmacol14: 164–171.
26.
Leucht S Wagenpfeil S Hamann J Kissling W (2004) Amisulpride is an “atypical” antipsychotic associated with low weight gain.Psychopharmacology173: 112–115.
27.
Lim CJ Trevino C Tampi RR (2006) Can olanzapine cause delirium in the elderly?Ann Pharmacother40: 135–138.
28.
Lingjaerde O Ahlfors UG Bech P Dencker SJ Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.Acta Psychiatr Scand334: 1–100.
29.
Liperoti R Pedone C Lapane KL Mor V Bernabei R Gambassi G (2005) Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents.Arch Intern Med165: 2677–2682.
30.
Masand P (2004) Clinical effectiveness of atypical antipsychotics in elderly patients with psychosis.Eur Neuropsychopharmacol14(Suppl. 4): S461–S469.
31.
Masand PS (2000) Side effects of antipsychotics in the elderly.J Clin Psychiatry61(Suppl. 8): 43–49.
32.
McKeage K Plosker GL (2004) Amisulpride: a review of its use in the management of schizophrenia.CNS Drugs18: 933–956.
33.
Möller HJ Riedel M Eich FX (2005) A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia.Eur Neuropsychopharmacol15 (Suppl. 3): S511 [abstract].
34.
Müller MJ Regenbogen B Härtter S Eich FX Hiemke C (2007) Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.J Psychiatr Res41: 673–679.
35.
Müller MJ Regenbogen B Sachse J Eich FX Härtter S Hiemke C (2006) Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.Pharmacopsychiatry39: 41–46.
36.
Müller-Spahn F (2005) Diagnosis and therapy of paranoid syndromes in the elderly.Fortschr Neurol Psychiatr73(Suppl. 1): S103–S106.
37.
Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.CNS Drugs19(Suppl. 1): 1–93.
38.
Patrick L Gaskovski P Rexroth D (2002) Cumulative illness and neuropsychological decline in hospitalized geriatric patients.Clin Neuropsychol16: 145–156.
39.
Sachse J Härtter S Weigmann H Hiemke C (2003) Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection.J Chromatogr B Analyt Technol Biomed Life Sci784: 405–410.
40.
Schmitt U Abou El-Ela A Guo LJ Glavinas H Krajcsi P Baron JM (2005) Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).J Neural Transm, doi: 10.1007/s00702-005-0367-4 [Epub ahead of print].
41.
Tariot PN Salzman C Yeung PP Pultz J Rak IW (2000) Long-term use of quetiapine in elderly patients with psychotic disorders.Clin Ther22: 1068–1084.
42.
Thürmann PA (2005) Gender-related differences in pharmacokinetics and pharmacodynamics.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz48: 536–540.
43.
Turnheim K (1998) Drug dosage in the elderly. Is it rational?Drugs Aging13: 357–379.
44.
Wang PS Schneeweiss S Avorn J Fischer MA Mogun H Solomon DH (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications.N Engl J Med353: 2335–2341.
45.
Weiss U Marksteiner J Kemmler G Saria A Aichhorn W (2005) Effects of age and sex on olanzapine plasma concentrations.J Clin Psychopharmacol25: 570–574.
